Canine Leishmaniasis Management Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012 to 2016 and Forecast 2017 to 2023

November 2017 | 219 pages | ID: C699ED8E980EN
Precision Business Insights (PBI)

Abstracts

Global Canine Leishmaniasis Management Market

Canine leishmaniasis is a vector-borne disease caused by the Leishmania infantum and Leishmania chagasi. Canine leishmaniasis is transmitted through the infected Phlebotominae flies. The severity of the canine leishmaniasis leads to the death of animals and high risk of disease transmission in humans and other dogs. The primary symptoms associated with the canine leishmaniasis include asthenia, anaemia, cachexia, weight loss, skin lesions, and muscular atrophy. In the later stage the symptoms like abnormal growth of nails, conjunctivitis, and renal failure may occur in the canines. The canine leishmaniasis can be prevented by administering the vaccines initially 3 doses with 3-week interval between them and an annual dose which increase the immunity in the canines.

The canine leishmaniasis management market is growing at a significant CAGR due to increase in adoption of canines. A rise in the prevalence of canine Leishmania, increase in the research and development for new vaccines for canine leishmaniasis management, rise in the expenditure for animal welfare and wellness, and patent filings for the various canine leishmaniasis management formulations might fuel the canine leishmaniasis management market over the forecast years. However, stringent regulatory policies for the approval of new vaccines for the canine leishmaniasis management, storage of vaccines, lack of awareness regarding canine leishmaniasis management, increase in the canine culling process, and dearth of canine leishmaniasis management products in the market might hamper the canine leishmaniasis management market growth in the forecast years.

Canine leishmaniasis management market is segmented on the basis of product type, disease type, route of administration, and end user

Based on the product type, canine leishmaniasis management market is segmented into the following:

• Canine leishmaniasis prevention
• Vaccines
• Canine leishmaniasis treatment
• Antibiotics
• Polyene antibiotics (Amphotericin B)
• Marbofloxacin
• Others
• Miltefosine
• Meglumine antimoniate
• Pentavalent antimonials
• Allopurinol combinations
• Paromomycin
• Others

Based on the disease type, canine leishmaniasis management market is segmented into the following:

• Visceral leishmaniasis
• Cutaneous leishmaniasis
• Mucocutaneous leishmaniasis

Based on the route of administration, canine leishmaniasis management market is segmented into the following:

• Oral
• Parenteral
• Topical

Based on the distribution channel, canine leishmaniasis management market is segmented into the following:

• Veterinary clinics
• Veterinary pharmacies
• Online pharmacies
• NGO’s
• Others

Global canine leishmaniasis management market is in the developing stage with several international players are actively involved in the development of formulations for the treatment and prevention of canine leishmaniasis. Increase in the research and development for canine leishmaniasis vaccines, product approval from various regulatory bodies such as EMEA and FDA, and launching of new products into the market might fuel the canine leishmaniasis management market over the forecast period. For instance, in March 2011, EMEA approved the marketing authorization in the Europe region for CaniLeish vaccine manufactured by Virbac S.A. Similarly, US Food and Drug Administration scientists are working with India and Brazil scientists for the development of a non-virulent vaccine to treat visceral leishmaniasis in canines.

Geographically, canine leishmaniasis management market is segmented into the following regions Viz. Europe, North America, Asia Pacific, Middle East and Africa, and Latin America. Europe holds significant share in the global canine leishmaniasis management market owing to the presence of tropical and subtropical areas which are favourable for the growth of sand flies. Spain, France, Greece, Italy and some other European countries have the highest prevalence of canine leishmaniasis. Increase in the research and development for Leishmania vaccines, rise in the expenditure of animal welfare and growing awareness about the canine leishmaniasis treatment might bolster the market. Asia Pacific canine leishmania management market growth over the forecast years attributed to poor hygienic conditions in the rural area, increase in the canine adoption rate, and the environmental conditions that favour the growth of sand flies. Increase in the canine leishmaniasis prevalence rate majorly in India, China, Bangladesh, Saudi Arabia, and UAE might fuel the canine leishmaniasis management market. North America holds a reasonable share due to increase in the adoption rate of canines (according to American Pet Products Association, approximately 78 Mn canines were owned in the U.S.).

Some of the players in canine leishmaniasis management market are Zoetis, Inc. (Pfizer) (U.S), Hertape Calier Saude Animal S.A. (Brazil), Virbac AH Inc. (France), Laboratories Leti (Spain), Bioiberica S.A. (Spain), and Sanofi S.A. (France) to name a few.

In September 2016, European commission authorized the marketing of Letifend vaccine manufactured by Laboratories Leti to treat canine leishmaniasis

Report Outline:

• The report provides granular level information about the market size, regional market share, and forecast from 2017-2023
• The report covers in-detail insights about the competitor’s overview, key findings, and their key strategies
• The report outlines drivers, restraints, challenges, and trends that are currently faced by the industry
• The report tracks recent innovations, key developments, and startup’s details that are working in the industry

Contents

1. EXECUTIVE SUMMARY

2. GLOBAL CANINE LEISHMANIASIS MANAGEMENT MARKET INTRODUCTION

2.1. Global Canine Leishmaniasis Management Market– Taxonomy
2.2. Global Canine Leishmaniasis Management Market–Definitions
  2.2.1. Product Type
  2.2.2. Disease Type

3. GLOBAL CANINE LEISHMANIASIS MANAGEMENT MARKET DYNAMICS

3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Canine Leishmaniasis Management Market Dynamics – Factors Impact Analysis
3.6. Global Canine Leishmaniasis Management Market– Recent Market Introductions

4. GLOBAL CANINE LEISHMANIASIS MANAGEMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023

4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Oppurtunity Analysis

5. GLOBAL CANINE LEISHMANIASIS MANAGEMENT MARKET FORECAST, BY PRODUCT TYPE, 2012 - 2016 AND FORECAST, 2017 - 2023

5.1. Vaccines
  5.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  5.1.3. Market Opportunity Analysis
5.2. Antibiotics
  5.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  5.2.3. Market Opportunity Analysis
5.3. Miltefosine
  5.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  5.3.3. Market Opportunity Analysis
5.4. Meglumine Antimoniate
  5.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  5.4.3. Market Opportunity Analysis
5.5. Pentavalent Antimonials
  5.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  5.5.3. Market Opportunity Analysis
5.6. Allopurinol Combinations
  5.6.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  5.6.3. Market Opportunity Analysis
5.7. Paromomycin
  5.7.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  5.7.3. Market Opportunity Analysis
5.8. Others
  5.8.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.8.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  5.8.3. Market Opportunity Analysis

6. GLOBAL CANINE LEISHMANIASIS MANAGEMENT MARKET FORECAST, BY DISEASE TYPE, 2012 - 2016 AND FORECAST, 2017 - 2023

6.1. Visceral Leishmaniasis
  6.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  6.1.3. Market Opportunity Analysis
6.2. Cutaneous Leishmaniasis
  6.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  6.2.3. Market Opportunity Analysis
6.3. Mucocutaneous Leishmaniasis
  6.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  6.3.3. Market Opportunity Analysis

7. GLOBAL CANINE LEISHMANIASIS MANAGEMENT MARKET FORECAST, BY ROUTE OF ADMINISTRATION, 2012 - 2016 AND FORECAST, 2017 - 2023

7.1. Oral
  7.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  7.1.3. Market Opportunity Analysis
7.2. Parenteral
  7.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  7.2.3. Market Opportunity Analysis
7.3. Topical
  7.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  7.3.3. Market Opportunity Analysis

8. GLOBAL CANINE LEISHMANIASIS MANAGEMENT MARKET FORECAST, BY DISTRIBUTION CHANNEL, 2012 - 2016 AND FORECAST, 2017 - 2023

8.1. Veterinary clinics
  8.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  8.1.3. Market Opportunity Analysis
8.2. Veterinary pharmacies
  8.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  8.2.3. Market Opportunity Analysis
8.3. Online pharmacies
  8.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  8.3.3. Market Opportunity Analysis
8.4. NGO’s
  8.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  8.4.3. Market Opportunity Analysis
8.5. Others
  8.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  8.5.3. Market Opportunity Analysis

9. GLOBAL CANINE LEISHMANIASIS MANAGEMENT MARKET FORECAST, BY REGION, 2012 - 2016 AND FORECAST, 2017 - 2023

9.1. North America
  9.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  9.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  9.1.3. Market Opportunity Analysis
9.2. Europe
  9.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  9.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  9.2.3. Market Opportunity Analysis
9.3. Asia-Pacific
  9.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  9.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  9.3.3. Market Opportunity Analysis
9.4. Latin America
  9.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  9.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  9.4.3. Market Opportunity Analysis
9.5. Middle East and Africa
  9.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  9.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  9.5.3. Market Opportunity Analysis
9.6. Global Canine Leishmaniasis Management Market- Opportunity Analysis Index - By Disease Type, By Product Type, By Route of Administration, By Distribution Channel, and Region, 2017 – 2023

10. NORTH AMERICA CANINE LEISHMANIASIS MANAGEMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

  10.1.1. Product Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    10.1.1.1. Canine Leishmaniasis Prevention
      10.1.1.1.1. Vaccines
    10.1.1.2. Canine Leishmaniasis Treatment
    10.1.1.3. Antibiotics
      10.1.1.3.1. Polyene Antibiotics (Amphotericin B)
      10.1.1.3.2. Marbofloxacin
      10.1.1.3.3. Others
    10.1.1.4. Miltefosine
    10.1.1.5. Meglumine Antimoniate
    10.1.1.6. Pentavalent Antimonials
    10.1.1.7. Allopurinol Combinations
    10.1.1.8. Paromomycin
    10.1.1.9. Others
  10.1.2. Disease Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    10.1.2.1. Visceral Leishmaniasis
    10.1.2.2. Cutaneous Leishmaniasis
    10.1.2.3. Mucocutaneous Leishmaniasis
  10.1.3. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    10.1.3.1. Oral
    10.1.3.2. Parenteral
    10.1.3.3. Topical
  10.1.4. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    10.1.4.1. Veterinary Clinics
    10.1.4.2. Veterinary Pharmacies
    10.1.4.3. Online Pharmacies
    10.1.4.4. NGO’s
    10.1.4.5. Others
  10.1.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
    10.1.5.1. U.S.
    10.1.5.2. Canada
  10.1.6. North America Canine Leishmaniasis Management Market- Opportunity Analysis Index - By Disease Type, By Product Type, By Route of Administration, By Distribution Channel, and Country, 2017 – 2023
  10.1.7. North America Canine Leishmaniasis Management Market Dynamics – Trends

11. EUROPE CANINE LEISHMANIASIS MANAGEMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

  11.1.1. Product Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    11.1.1.1. Canine Leishmaniasis Prevention
      11.1.1.1.1. Vaccines
    11.1.1.2. Canine Leishmaniasis Treatment
    11.1.1.3. Antibiotics
      11.1.1.3.1. Polyene Antibiotics (Amphotericin B)
      11.1.1.3.2. Marbofloxacin
      11.1.1.3.3. Others
    11.1.1.4. Miltefosine
    11.1.1.5. Meglumine Antimoniate
    11.1.1.6. Pentavalent Antimonials
    11.1.1.7. Allopurinol Combinations
    11.1.1.8. Paromomycin
    11.1.1.9. Others
  11.1.2. Disease Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    11.1.2.1. Visceral Leishmaniasis
    11.1.2.2. Cutaneous Leishmaniasis
    11.1.2.3. Mucocutaneous Leishmaniasis
  11.1.3. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    11.1.3.1. Oral
    11.1.3.2. Parenteral
    11.1.3.3. Topical
  11.1.4. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    11.1.4.1. Veterinary Clinics
    11.1.4.2. Veterinary Pharmacies
    11.1.4.3. Online Pharmacies
    11.1.4.4. NGO’s
    11.1.4.5. Others
  11.1.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    11.1.5.1. Germany
    11.1.5.2. UK
    11.1.5.3. France
    11.1.5.4. Spain
    11.1.5.5. Italy
    11.1.5.6. Russia
    11.1.5.7. Poland
    11.1.5.8. Rest of Europe
  11.1.6. Europe Canine Leishmaniasis Management Market- Opportunity Analysis Index - By Disease Type, By Product Type, By Route of Administration, By Distribution Channel, and Country, 2017 – 2023
  11.1.7. Europe Canine Leishmaniasis Management Market Dynamics – Trends

12. ASIA-PACIFIC CANINE LEISHMANIASIS MANAGEMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

  12.1.1. Product Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    12.1.1.1. Canine Leishmaniasis Prevention
      12.1.1.1.1. Vaccines
    12.1.1.2. Canine Leishmaniasis Treatment
    12.1.1.3. Antibiotics
      12.1.1.3.1. Polyene Antibiotics (Amphotericin B)
      12.1.1.3.2. Marbofloxacin
      12.1.1.3.3. Others
    12.1.1.4. Miltefosine
    12.1.1.5. Meglumine Antimoniate
    12.1.1.6. Pentavalent Antimonials
    12.1.1.7. Allopurinol Combinations
    12.1.1.8. Paromomycin
    12.1.1.9. Others
  12.1.2. Disease Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    12.1.2.1. Visceral Leishmaniasis
    12.1.2.2. Cutaneous Leishmaniasis
    12.1.2.3. Mucocutaneous Leishmaniasis
  12.1.3. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    12.1.3.1. Oral
    12.1.3.2. Parenteral
    12.1.3.3. Topical
  12.1.4. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    12.1.4.1. Veterinary Clinics
    12.1.4.2. Veterinary Pharmacies
    12.1.4.3. Online Pharmacies
    12.1.4.4. NGO’s
    12.1.4.5. Others
  12.1.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn),
Y-o-Y Growth (%), and Market Share (%)
    12.1.5.1. Japan
    12.1.5.2. China
    12.1.5.3. India
    12.1.5.4. ASEAN
    12.1.5.5. Australia & New Zealand
    12.1.5.6. Rest of Asia-Pacific
  12.1.6. Asia-Pacific Canine Leishmaniasis Management Market- Opportunity Analysis Index - By Disease Type, By Product Type, By Route of Administration, By Distribution Channel, and Country, 2017 – 2023
  12.1.7. Asia-Pacific Canine Leishmaniasis Management Market Dynamics – Trends

13. LATIN AMERICA CANINE LEISHMANIASIS MANAGEMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

  13.1.1. Product Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    13.1.1.1. Canine Leishmaniasis Prevention
      13.1.1.1.1. Vaccines
    13.1.1.2. Canine Leishmaniasis Treatment
    13.1.1.3. Antibiotics
      13.1.1.3.1. Polyene Antibiotics (Amphotericin B)
      13.1.1.3.2. Marbofloxacin
      13.1.1.3.3. Others
    13.1.1.4. Miltefosine
    13.1.1.5. Meglumine Antimoniate
    13.1.1.6. Pentavalent Antimonials
    13.1.1.7. Allopurinol Combinations
    13.1.1.8. Paromomycin
    13.1.1.9. Others
  13.1.2. Disease Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    13.1.2.1. Visceral Leishmaniasis
    13.1.2.2. Cutaneous Leishmaniasis
    13.1.2.3. Mucocutaneous Leishmaniasis
  13.1.3. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    13.1.3.1. Oral
    13.1.3.2. Parenteral
    13.1.3.3. Topical
  13.1.4. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    13.1.4.1. Veterinary Clinics
    13.1.4.2. Veterinary Pharmacies
    13.1.4.3. Online Pharmacies
    13.1.4.4. NGO’s
    13.1.4.5. Others
  13.1.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    13.1.5.1. Brazil
    13.1.5.2. Mexico
    13.1.5.3. Argentina
    13.1.5.4. Venezuela
    13.1.5.5. Rest of Latin America
  13.1.6. Latin America Canine Leishmaniasis Management Market- Opportunity Analysis Index - By Disease Type, By Product Type, By Route of Administration, By Distribution Channel, and Country, 2017 – 2023
  13.1.7. Latin America Canine Leishmaniasis Management Market Dynamics – Trends

14. MIDDLE EAST & AFRICA CANINE LEISHMANIASIS MANAGEMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

  14.1.1. Product Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    14.1.1.1. Canine Leishmaniasis Prevention
      14.1.1.1.1. Vaccines
    14.1.1.2. Canine Leishmaniasis Treatment
    14.1.1.3. Antibiotics
      14.1.1.3.1. Polyene Antibiotics (Amphotericin B)
      14.1.1.3.2. Marbofloxacin
      14.1.1.3.3. Others
    14.1.1.4. Miltefosine
    14.1.1.5. Meglumine Antimoniate
    14.1.1.6. Pentavalent Antimonials
    14.1.1.7. Allopurinol Combinations
    14.1.1.8. Paromomycin
    14.1.1.9. Others
  14.1.2. Disease Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    14.1.2.1. Visceral Leishmaniasis
    14.1.2.2. Cutaneous Leishmaniasis
    14.1.2.3. Mucocutaneous Leishmaniasis
  14.1.3. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    14.1.3.1. Oral
    14.1.3.2. Parenteral
    14.1.3.3. Topical
  14.1.4. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    14.1.4.1. Veterinary Clinics
    14.1.4.2. Veterinary Pharmacies
    14.1.4.3. Online Pharmacies
    14.1.4.4. NGO’s
    14.1.4.5. Others
  14.1.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
    14.1.5.1. Gulf Cooperation Council (GCC) Countries
    14.1.5.2. Israel
    14.1.5.3. South Africa
    14.1.5.4. Rest of MEA
  14.1.6. MEA Canine Leishmaniasis Management Market- Opportunity Analysis Index - By Disease Type, By Product Type, By Route of Administration, By Distribution Channel, and Country, 2017 – 2023
  14.1.7. MEA Canine Leishmaniasis Management Market Dynamics – Trends

15. COMPETITION LANDSCAPE

15.1. Strategic Dashboard of Top Market Players
15.2. Company Profiles (Introduction, Financial Analysis, Drug & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
  15.2.1. Zoetis, Inc. (Pfizer) (U.S)
  15.2.2. Hertape Calier Saude Animal S.A. (Brazil)
  15.2.3. Virbac AH Inc. (France)
  15.2.4. Laboratories Leti (Spain)
  15.2.5. Bioiberica S.A. (Spain)

16. RESEARCH METHODOLOGY

17. KEY ASSUMPTIONS AND ACRONYMS